Marcin Trojanowski, MD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine

MD, Medical University of South Carolina
BS, College of Charleston

Marcin Trojanowski, MD Clinical Assistant Professor of Medicine Director, Rheumatology Clinic Director, Scleroderma Program Section of Rheumatology Chobanian and Avedisian School of Medicine 72 East Concord Street, 5th floor Boston, MA 02118 Marcin Trojanowski, MD is a Clinical Assistant Professor of Medicine in Rheumatology at Chobanian and Avedisian School of Medicine. He has a decade of experience in treatment of systemic sclerosis as well as a passion for medical teaching.

Prior to his arrival at BUMC, Dr. Trojanowski was the head of the Scleroderma Clinic at UAB where he was the primary referral in the region. In this role he carved out a regional role in both systemic sclerosis as well as CTD-ILD. At BUMC, he has overseen an ever expanding role within the scleroderma clinic. He also serves as the Clinical Director of the Division of Rheumatology. Dr. Trojanowski has worked on many translational and epidemiological research studies such as the Genome Research in African American Scleroderma Patients (GRASP). He has participated in directly sponsored pharmaceutical research as the principle and sub investigator of dozens of drug trials in systemic sclerosis, systemic lupus and more recently COVID 19.

In education, Dr. Trojanowski excelled at UAB as a top ten teacher in the Department of Medicine as well as a leading teacher in the Division of Rheumatology. He was a member of the Strategic Committee on Education at UAB Department of Medicine. At Boston University, Dr. Trojanowski is the director of the rheumatology musculoskeletal module for the second-year medical students and has developed a multidisciplinary problem-based learning module for first year students.

Chief Clinical Interests: Systemic Sclerosis, Connective Tissue Diseases, and Lung Disease in Connective Tissue Disease

Clinic Director
Boston University Chobanian & Avedisian School of Medicine

Director, Scleroderma Program
Boston University Chobanian & Avedisian School of Medicine

Boston University
Arthritis & Autoimmune Diseases Research Center

A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD) PR200-104
09/20/2022 - 09/20/2025 (Subcontract PI)
PPD Development LLC Prometheus Bio, Inc

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous
11/12/2021 - 11/11/2024 (PI)
Horizon Therapeutics

IgPro10_2001 A Randomized, Multicenter, double blind, placebo controlled, Phase 2 study to evaluate the efficacy and safety of IgPro10 (Intravenous Immunoglobulin, Privige) For the treatment of Adult
08/27/2020 - 08/27/2023 (PI)
CSL Behring LLC

03/15/2019 - 03/14/2023 (PI)
Kadmon Corporation, LLC

Protocol # ML30172 - Scleroderma Lung Study III: Combining of anti-fibrotic effects of Pirfenidone with Mycophenolate to treat scleroderma-related interstitial lung disease
06/29/2018 - 02/28/2023 (PI)
University of California, Los Angeles

Protocol # 1199.225, An open-label extension trial to assess the long term safety of nintedanib in patients with‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD)
02/08/2018 - 02/07/2023 (PI)
Boehringer Ingelheim Pharmaceuticals, Inc.

Genome Research in African American Sclerodema Patients (GRASP)
04/05/2017 - 04/04/2022 (Subcontract PI)
Johns Hopkins University Scleroderma Res Fdn

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
10/18/2017 - 02/28/2022 (PI)
Corbus Pharmaceuticals Holdings, Inc.

Protocol # ITN075AI, (BRAVOS) - Evaluation of Brentuximab Vedotin in Diffuse Cutaneous Systemic Sclerosis
02/01/2017 - 01/31/2022 (Subcontract PI)
Benaroya Research Institute at Virginia Mason NIH NIAID

Protocol #CPI-IFE-004 "A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the safety and efficacy of Ifetroban in Patients with Diffuse Cutaneous Systemic Sclerosis or Systemic-Scl
01/03/2019 - 01/03/2021 (PI)
Cumberland Pharmaceuticals Inc.

Showing 10 of 11 results. Show All Results


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Vakhshoorzadeh J, Lui JK, Sangani RA, Trojanowski MA, Bujor AM, LaValley MP, Klings ES. Emphysema and interstitial lung disease in systemic sclerosis-related pulmonary hypertension. Respir Med. 2023 Sep; 216:107333.View Related Profiles. PMID: 37336329; DOI: 10.1016/j.rmed.2023.107333;
  2. Pilitsi E, Kennamer B, Trepanowski N, Gonzalez R, Trojanowski M, Phillips T, Lam CS. Cannabis arteritis presenting with Raynaud's and digital ulcerations: a case-based review of a controversial thromboangiitis obliterans-like condition. Clin Rheumatol. 2023 Jul; 42(7):1981-1985.View Related Profiles. PMID: 37097526
  3. Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Correction to: Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2023 Jan 20.View Related Profiles. PMID: 36662449
  4. Lui JK, Gillmeyer KR, Sangani RA, Smyth RJ, Gopal DM, Trojanowski MA, Bujor AM, Soylemez Wiener R, LaValley MP, Klings ES. A Multimodal Prediction Model for Diagnosing Pulmonary Hypertension in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2023 Jul; 75(7):1462-1468.View Related Profiles. PMID: 35678779; PMCID: PMC9732142; DOI: 10.1002/acr.24969;
  5. Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2023 Jan 06.View Related Profiles. PMID: 36607535; DOI: 10.1007/s10557-022-07420-1;
  6. Sangani RA, Lui JK, Gillmeyer KR, Trojanowski MA, Bujor AM, LaValley MP, Klings ES. Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity. Pulm Circ. 2022 Oct; 12(4):e12117.View Related Profiles. PMID: 36238967; PMCID: PMC9535436; DOI: 10.1002/pul2.12117;
  7. Lui JK, Sangani RA, Chen CA, Bujor AM, Trojanowski MA, Gopal DM, LaValley MP, Soylemez Wiener R, Klings ES. Prognostic Value of Cardiac Axis Deviation in Systemic Sclerosis-Related Pulmonary Hypertension. Arthritis Care Res (Hoboken). 2022 Jul; 74(7):1219-1226.View Related Profiles. PMID: 34085410; PMCID: PMC8639831; DOI: 10.1002/acr.24724;
  8. Mazzotta C, Marden G, Farina A, Bujor A, Trojanowski MA, Trojanowska M. FLI1 and ERG protein degradation is regulated via Cathepsin B lysosomal pathway in human dermal microvascular endothelial cells. Microcirculation. 2021 01; 28(1):e12660.View Related Profiles. PMID: 32979864; PMCID: PMC7988617; DOI: 10.1111/micc.12660;
  9. Marden G, Wan Q, Wilks J, Nevin K, Feeney M, Wisniacki N, Trojanowski M, Bujor A, Stawski L, Trojanowska M. The role of the oncostatin M/OSM receptor ß axis in activating dermal microvascular endothelial cells in systemic sclerosis. Arthritis Res Ther. 2020 07 31; 22(1):179.View Related Profiles. PMID: 32736577; PMCID: PMC7393919; DOI: 10.1186/s13075-020-02266-0;
  10. Gourh P, Safran SA, Alexander T, Boyden SE, Morgan ND, Shah AA, Mayes MD, Doumatey A, Bentley AR, Shriner D, Domsic RT, Medsger TA, Ramos PS, Silver RM, Steen VD, Varga J, Hsu V, Saketkoo LA, Schiopu E, Khanna D, Gordon JK, Kron B, Criswell LA, Gladue H, Derk CT, Bernstein EJ, Bridges SL, Shanmugam VK, Kolstad KD, Chung L, Kafaja S, Jan R, Trojanowski M, Goldberg A, Korman BD, Steinbach PJ, Chandrasekharappa SC, Mullikin JC, Adeyemo A, Rotimi C, Wigley FM, Kastner DL, Boin F, Remmers EF. HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. Proc Natl Acad Sci U S A. 2020 01 07; 117(1):552-562. PMID: 31871193; PMCID: PMC6955366; DOI: 10.1073/pnas.1906593116;
Showing 10 of 12 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 12 publications over 6 distinct years, with a maximum of 5 publications in 2023


In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Systemic Lupus
Contact for Mentoring:

72 E. Concord St Evans Building
Boston MA 02118
Google Map

Trojanowski's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department